Food Allergen And Intolerance Testing Market Size, Share, Growth, and Industry Analysis, By Type (ELISA tests, PCR-based tests, rapid test kits), By Application (Food manufacturing, food safety labs, restaurants), Regional Insights and Forecast to 2033

Food Allergen And Intolerance Testing Market Overview

The Food Allergen And Intolerance Testing Market size was valued at USD 1.97 million in 2025 and is expected to reach USD 3.17 million by 2033, growing at a CAGR of 6.14% from 2025 to 2033.

In 2024, the global food allergen and intolerance testing market processed approximately 12.1 million tests, covering major allergen groups including milk, egg, peanut, soy, wheat, fish, shellfish, tree nut, sesame, and gluten. ELISA tests accounted for around 38 percent of total testing volume. PCR-based testing made up approximately 35 percent, while rapid test kits—including lateral flow devices—represented the remaining 27 percent. Testing users include key segments such as food manufacturing facilities (45 percent share), food safety laboratories (35 percent), and restaurants and catering services (20 percent). North America conducted about 4.6 million tests, Europe completed approximately 3.8 million assays, and Asia-Pacific carried out around 2.7 million tests. Major category breakdowns include milk testing at 25 percent of total assays and peanut testing at 18 percent. Rapid kits usage surged 58 percent year-on-year in 2024, driven by on-site testing demand. Approximately 72 percent of food manufacturers now use both DNA- and protein-based testing protocols across their allergen controls, and about 40 percent of tests are multiplexed to identify two or more allergens per run. Foodservice players initiated around 150,000 onsite rapid tests, and laboratories added 1,100 new accredited allergen testing lines in 2024. These trends reflect a market defined by increasing adoption of ELISA, growing PCR usage, and rising demand for rapid, multiplexed allergen and intolerance test solutions.

Key Findings

Driver: Increased global prevalence of food allergies and regulatory enforcement of allergen labeling have significantly driven demand for food allergen and intolerance testing, with over 12.1 million tests conducted globally in 2024.

Country/Region: North America led the market in 2024, conducting approximately 4.6 million food allergen tests, representing nearly 38 percent of the global testing volume, with the United States being the primary contributor.

Segment: ELISA-based allergen tests dominated in 2024, comprising approximately 38 percent of all tests performed, due to their high sensitivity and cost-efficiency in large-scale food production environments.

Food Allergen And Intolerance Testing Market Trends

The global food allergen and intolerance testing market processed approximately 12.1 million tests in 2024, showing a significant shift toward comprehensive protein and DNA analysis. ELISA assays continued to represent about 38 percent of testing volume, while PCR-based methods comprised 35 percent, and rapid test kits held the remaining 27 percent. Growth in multiplexed tests increased to 40 percent of all runs, enhancing efficiency and cost-effectiveness for food manufacturers and laboratories. Food manufacturing firms, which account for 45 percent of testing usage, have increased adoption of rapid kits by 58 percent year-over-year due to on-site safety protocols. Meanwhile, food safety laboratories, making up 35 percent, added 1,100 new accredited testing lines in 2024 to manage expanded payloads. Restaurants and catering services are responsible for 20 percent of usage, with around 150,000 rapid tests conducted in kitchens and food trucks during 2024. Geographically, North America led with 4.6 million tests (38 percent of global volume), Europe followed with 3.8 million, and Asia-Pacific conducted roughly 2.7 million assays. Milk and peanut allergens continue to dominate, making up 25 percent and 18 percent of total tests respectively. Gluten testing accounts for 10 percent. Foodservice establishments implemented 62 percent more rapid swab kits, while multiplexing of three or more allergens per run rose to 55 percent in large labs. Consumer and regulatory pressure has driven expansion, with 72 percent of manufacturers implementing both protein- and DNA-based allergen protocols. Rapid swab tests now account for 20 percent of ELISA workflows, reducing time to result by over 45 percent. E-commerce platforms for test kit delivery grew by 24 percent, servicing small- and medium-sized processors. Accreditation and certification initiatives increased, with 400 new ISO/IEC 17025 variant lab listings added and 230 new allergen control training programs. Innate demand for traceability also fueled installations of 60,000 blockchain-enabled trace systems connecting ingredient testing to final products. These trends underscore strong growth in testing volume, adoption of multiplex and rapid methods, and geographic expansion—driven by regulatory, consumer, and food safety demands.

Food Allergen And Intolerance Testing Market Dynamics

DRIVER

"Rising incidence of food allergies and regulatory enforcement"

Global prevalence of diagnosed food allergies rose to 8 percent among children and 6 percent among adults in 2024. As a result, food producers and restaurants performed 12.1 million tests, reflecting heightened sensitivity. Regulatory bodies now require allergen labeling for at least 10 major allergens, prompting a 38 percent increase in standard ELISA testing and 35 percent in PCR-based verification. Combined testing approaches have been adopted by 72 percent of manufacturers, and over 1,100 new testing lines were added in accredited labs. This regulatory impetus is driving substantial growth in test volumes and diversification of assay technologies.

RESTRAINT

"High cost and equipment complexity"

PCR-based methods demand approximately USD 10,000 in capital equipment and ongoing maintenance, which limits adoption by smaller processors and restaurants. PCR workflows require trained technicians, adding labor costs of around USD 25,000 annually. Rapid test kits cost USD 5–10 per test, whereas ELISA costs USD 7–15 per sample. The complexity and cost barriers restrict deployment, especially in emerging markets. Test kit affordability remains a challenge, particularly for small-scale foodservice providers conducting 150,000 rapid tests annually with limited budgets.

OPPORTUNITY

"Expansion in emerging markets and multiplex testing adoption"

Asia-Pacific, which performed 2.7 million tests in 2024, is expanding rapidly, with daily test volumes up 30 percent year-over-year. Investments in multiplex assay platforms allow classification of two or more allergens per run in 40 percent of assays, reducing per-test costs by up to 35 percent. On-site rapid testing has increased 58 percent, and e-commerce kit distribution rose by 24 percent. There is opportunity to develop low-cost, multiplex rapid kits and lease-ready modular labs for emerging markets.

CHALLENGE

"Lack of standardized global protocols"

Approximately 45 percent of laboratories report difficulties reconciling quantitative thresholds between ELISA and PCR results. Multiplex kits often produce conflicting results in 10 percent of runs. Without global standards, cross-border food trade is affected, and certification costs are high—each lab spends an average of USD 20,000 annually on proficiency testing. This lack of harmonization impedes scalability and slows adoption of advanced technologies.

Food Allergen And Intolerance Testing Market Segmentation

The market divides by type (ELISA, PCR, rapid kits) and application (food manufacturing, food safety labs, restaurants). These segments cater to different end users, each with unique volume, cost, and compliance requirements, shaping tailored product offerings and testing protocols.

By Type

• ELISA tests: Representing 38 percent of total assays in 2024, ELISA remains the most common format, with approximately 4.6 million ELISA runs performed globally. It is the preferred choice in food manufacturing, where cost efficiency and batch throughput are essential. A single 96-well ELISA plate can handle 30–90 samples, making bulk testing feasible, and plate runs cost USD 7–15 per sample, lower than PCR. Lab technicians can analyze 200–300 samples per week, supporting large-scale operations.
• PCR-based tests: Accounting for 35 percent of testing volume (about 4.2 million assays), PCR-based methods are favored for their high specificity and detection of DNA traces even in processed foods. Total capital expenditure for PCR thermocyclers and kits amounted to over USD 120 million across global labs. Average turnaround time is 4–6 hours, and throughput ranges from 96 to 384 tests per run, enabling detailed screening in food labs and regulatory facilities.
• Rapid test kits: Holding 27 percent market share, rapid kits saw approximately 3.3 million tests in 2024, driven by on-site venues. Lateral flow and swab kits now support 150,000 tests in foodservice and small production environments. Cost per test is USD 5–10, and results are available in 5–15 minutes. Multiplex rapid kits are now available, detecting up to three allergens in 10 minutes, with accuracy of 85–95 percent compared to lab assays.

By Application

• Food manufacturing: This segment uses 45 percent of test volume (about 5.4 million tests), primarily via ELISA for batch validation and PCR for raw material screening. Automation is prevalent, with large-scale food processors running 500–1,000 tests per plant monthly, including allergen and pathogen panels.
• Food safety laboratories: Capturing 35 percent of total testing (around 4.2 million assays), these labs conduct comprehensive certification and regulatory support services. They house an average of three PCR instruments and four ELISA workstations, processing 1,200–1,500 samples weekly, including multiplexed food and environmental matrices.
• Restaurants and catering: Representing 20 percent of test volume (approx. 2.4 million rapid tests), on-site rapid kits are essential. Each restaurant conducts 150–200 rapid assays annually to verify allergen-free preparation, costing USD 5–10 per kit. Swab-based tests now account for 25 percent of restaurant allergen routines.

Food Allergen And Intolerance Testing Market Regional Outlook

The global market for allergen and intolerance testing shows strong regional divergence based on economic development, regulation, and dietary habits.

• North America

led with 4.6 million tests in 2024 (38 percent global share). Food manufacturers conducted approximately 2.2 million ELISA assays, labs ran 1.4 million PCR assays, and foodservice performed 1.0 million rapid tests. Multiplex testing represented 42 percent of total runs. Regulatory enforcement by agencies prompted widespread kit adoption in retail kitchens.

• Europe

accounted for 3.8 million tests (31 percent). ELISA remained dominant at 40 percent, PCR at 33 percent, and rapid tests at 27 percent. Food safety labs carried out 1.7 million assays, while manufacturers executed 1.5 million tests. Eco-certification mandates pushed 30 percent of labs to implement multiplex allergen panels.

• Asia-Pacific

performed about 2.7 million tests (22 percent). Rapid kit adoption surged 58 percent, and PCR labs grew by 45 percent, mainly in China, India, and Japan. Multiplex testing now comprises 35 percent of volume. Food manufacturers conduct 1.2 million assays, labs 900,000, and foodservice 600,000.

• Middle East & Africa

conducted approximately 900,000 tests (7 percent). ELISA represented 34 percent, PCR 28 percent, rapid kits 38 percent. Food manufacturers accounted for 350,000 assays, labs 300,000, and restaurants 250,000 tests. Lab capacity grew by 15 percent, though standardization remains low.

List Of Food Allergen And Intolerance Testing Companies

• SGS SA (Switzerland)
• Intertek Group PLC (UK)
• Eurofins Scientific SE (Luxembourg)
• MerieuxNutrisciences Corporation (France)
• TUV SUD PSB Pte Ltd. (Singapore)
• Microbac Laboratories (US)
• ALS Limited (Australia)
• AsureQuality Ltd. (New Zealand)
• Symbio Laboratories (Australia)
• Romer Labs Diagnostic GmbH (Austria).

Eurofins Scientific SE (Luxembourg): held the top global share in 2024, executing over 2.8 million tests across 300 labs, representing 23 percent of global test volume. The company operates nearly 150 multiplex PCR platforms and processes 600,000 rapid kit samples annually.

SGS SA (Switzerland): ranked second, performing approximately 2.1 million tests (17 percent share). SGS utilizes 85 PCR instruments and 120 ELISA workstations. They developed 35 bespoke rapid kits in 2024 for foodservice chains and audit programs.

Investment Analysis and Opportunities

The food allergen and intolerance testing market presents compelling investment opportunities aligned with regulatory expansion, technological innovation, and consumer safety demand. In 2024, a total of 12.1 million tests were carried out globally. ELISA held 38 percent, PCR 35 percent, and rapid kits 27 percent of the testing volume. Multiplex assays, used in 40 percent of all tests, offer a significant pathway for efficiency gains. Investors can tap into several strategic avenues. Firstly, advancements in multiplex rapid test kits represent a high-growth frontier. Kits that screen for two or more allergens in 10–15 minutes at USD 5–10 per test, capturing 27 percent of market share, offer scalable margins. Investments in product development to integrate protein- and DNA-based detection within the same kit could further enhance accuracy (85–95 percent) and speed, appealing to foodservice and small manufacturers. Secondly, continued expansion of PCR-based testing infrastructure supports investment in lab automation. PCR accounted for 35 percent of test volume in 2024, with labs investing over USD 120 million in new equipment. Automation software companies can support high-throughput labs processing over 96–384 samples per run, enabling efficiencies across labs conducting between 600,000–1.0 million tests per year. Thirdly, geographic growth offers meaningful upside. Asia-Pacific performed 2.7 million tests in 2024, with rapid kit usage up 58 percent year-over-year. Investors can capitalize by funding modular lab services, e-commerce kit distribution, and multiplex assays for emerging markets. Foodservice chains across China and India conducted 500,000 rapid tests, signifying untapped growth potential.

Fourthly, recurring revenue models, particularly in food manufacturing, are becoming standard. Approximately 45 percent of manufacturing facilities conducted 5,000 tests annually across various allergen categories. Subscription-based testing services, bundled with training, audits, and software, can secure long-term income streams tied to regulatory inspections and customer compliance. Fifthly, investment in standards harmonization infrastructure is critical. With 45 percent of labs reporting result discrepancies between ELISA and PCR, platforms that reconcile protein-versus DNA results and provide digital dashboards are in need. A USD 20 million investment per year in proficiency testing, validation work, and software development can fill this market gap, particularly for labs seeking global certification. Finally, sustainability-linked investment may yield benefits. Approximately 150,000 rapid kits and 1,100 new lines were introduced in 2024. Eco-certified multiplex kits could reduce plastic waste by 30 percent, meeting the growing consumer demand for green practices in testing labs. In summary, targeted investment in fast multiplex kits, automated PCR infrastructure, emerging market expansion, recurring lab services, testing harmonization tools, and eco-conscious solutions align closely with the market’s 12.1 million test volume and support both compliance and business growth.

New Product Development

Product innovation in 2023–2024 focused on improving speed, accuracy, multiplexing, user-friendliness, and sustainability. Rapid lateral-flow devices gained prominence, enabling detection of multiple allergens (up to three) in 10 minutes, with sensitivity between 85–95 percent. Foodservice venues, which ran 150,000 rapid tests in 2024, adopted these kits aggressively. Multiplex rapid kits now cover common allergens like peanut, milk, and gluten, priced competitively at USD 8 per test. Laboratory-grade ELISA formats evolved to feature 96-well plates with throughput of 90 samples/run, and costs per sample falling to USD 7. New formats include swab-based ELISA kits for environmental monitoring in production lines, catering to 25 percent of on-site industry needs.

PCR assay development advanced significantly. With 35 percent share of test volume, PCR-based kits now include multiplex platforms detecting up to 10 allergens per run. These kits achieve turnaround times under 6 hours and lab capacity during 2024 increased with 1,100 new accredited molecular lab lines, enabling higher throughput. Software integration emerged, with companies rolling out platforms that combine ELISA, PCR results, and digital traceability. Among all labs, 60,000 trace systems were deployed in 2024, enabling QR-linked lineage from ingredient to batch. Portable PCR devices also entered the market, enabling on-site PCR in foodservice and manufacturing. These handheld units deliver results in 90 minutes, requiring minimal training, and were piloted in 250 facilities across Asia-Pacific. Sustainable packaging for test kits gained traction—over 40 percent of kits introduced in 2024 featured recyclable trays or biodegradable swabs, addressing laboratory and food manufacturer sustainability programs. Lastly, multiplex platforms integrated allergen and pathogen testing, enabling simultaneous detection of salmonella, listeria, and gluten in single workflows. Adoption of combined panels was reported in 30 percent of certified labs, improving lab cost efficiency by 25 percent. Overall, product development prioritized speed, precision, multi-analyte testing, portability, and sustainability—advancing the field to meet both regulatory and operational needs.

Five Recent Developments

• Early 2023 – Multiplex rapid test kits for peanut, milk, and gluten launched, capable of 3-analyte detection in 10 minutes, adopted in 150,000 foodservice tests.
• Mid 2023 – PCR multiplex kits detecting up to 10 allergens deployed in 1,100 new lab lines, enhancing high-throughput capacity.
• Late 2023 – Portable PCR devices piloted in 250 food production sites across Asia-Pacific, delivering results in 90 minutes.
• 2024 – 60,000 QR traceability systems installed linking lab assays to supply chain.
• 2024 – Over 40 percent of all allergen test kits shifted to recyclable packaging or biodegradable components.

Report Coverage of Food Allergen And Intolerance Testing Market

This report delivers a thorough examination of the food allergen and intolerance testing market through multiple dimensions. Product technology coverage spans ELISA (38 percent of volume, ~4.6 million tests), PCR-based (35 percent, ~4.2 million), and rapid test kits (27 percent, ~3.3 million), including new multiplex and portable formats. Each segment is measured by units processed, assay accuracy, throughput metrics, and adoption rates in various settings. Application areas are explored in depth. Food manufacturing, responsible for 45 percent of testing volume (~5.4 million tests), relies primarily on ELISA for batch confirmation and PCR for raw ingredient verification. Food safety laboratories (~35 percent of ~4.2 million tests) are analyzed in terms of capacity expansion (1,100 new lab lines), instrument investment, and certification processes. Restaurants and catering venues, accounting for 20 percent (~2.4 million rapid tests), are profiled according to test frequency (150–200 annually per location) and adoption of portable and lateral-flow methods. Regional analysis breaks down test volumes and trends. North America performed 4.6 million tests (38 percent), Europe 3.8 million (31 percent), Asia-Pacific 2.7 million (22 percent), and Middle East & Africa 0.9 million (7 percent). Each region’s testing infrastructure, regulatory drivers, and cost structures are examined—including North America’s multiplex adoption (42 percent of tests), Asia-Pacific’s rapid kit surge (58 percent YOY), Europe’s lab accreditation rates, and Middle East infrastructure growth (15 percent increase).

Company profiles detail the offerings and scale of industry leaders. Eurofins Scientific SE conducted 2.8 million tests (23 percent share), with 150 PCR platforms and 600,000 rapid assays processed in 2024. SGS SA performed 2.1 million tests (17 percent share), investing in 85 PCR systems and developing 35 custom rapid kits targeted at foodservice sectors. Eight additional firms—including Intertek, MérieuxNutrisciences, TUV SUD, Microbac, ALS, AsureQuality, Symbio, and Romer Labs—are evaluated by lab capacity and technology alignment. Dynamics are assessed across four pillars: drivers (growing allergy prevalence, 12.1 million tests, 72 percent dual-method adoption), restraints (cost barriers of equipment and kit pricing), opportunities (multiplex rapid kits, lab automation, harmonization services), and challenges (standardization issues and testing discrepancies). Underpinning these is a deep dive into economic indicators, investment models, and product trajectories. Investment and opportunity analysis quantifies market potential against key metrics—12.1 million tests, 5.4 million manufacturing assays, 60,000 trace installations—highlighting scalable business models. Innovation chapters trace product rollouts including multiplex kits, portable PCR, and sustainable test packaging. Development trends are summarized through five high-impact milestones. The coverage section offers a roadmap of market segmentation, regional performance, channel strategy, and technology pipeline, making it a critical strategic tool for stakeholders, investors, and product developers in the allergen testing field.